ExodusPoint Capital Management LP Has $579,000 Stock Holdings in Accolade, Inc. (NASDAQ:ACCD)

ExodusPoint Capital Management LP boosted its holdings in Accolade, Inc. (NASDAQ:ACCD - Free Report) by 129.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 169,223 shares of the company's stock after buying an additional 95,498 shares during the quarter. ExodusPoint Capital Management LP owned 0.21% of Accolade worth $579,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. Rhumbline Advisers lifted its stake in Accolade by 1.7% during the fourth quarter. Rhumbline Advisers now owns 115,136 shares of the company's stock valued at $394,000 after buying an additional 1,967 shares in the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd boosted its stake in Accolade by 49.9% in the 4th quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 17,804 shares of the company's stock worth $61,000 after purchasing an additional 5,929 shares during the period. Inspire Investing LLC grew its position in Accolade by 9.9% during the 4th quarter. Inspire Investing LLC now owns 117,216 shares of the company's stock worth $401,000 after purchasing an additional 10,537 shares in the last quarter. SG Americas Securities LLC lifted its holdings in shares of Accolade by 36.1% in the fourth quarter. SG Americas Securities LLC now owns 40,498 shares of the company's stock valued at $139,000 after purchasing an additional 10,749 shares in the last quarter. Finally, Pallas Capital Advisors LLC acquired a new stake in shares of Accolade in the fourth quarter worth $38,000. Institutional investors and hedge funds own 84.99% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on ACCD. Raymond James reiterated a "market perform" rating on shares of Accolade in a report on Thursday, January 9th. William Blair lowered Accolade from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, January 8th. Stephens reiterated an "equal weight" rating and set a $7.03 price target on shares of Accolade in a report on Wednesday, February 12th. Needham & Company LLC restated a "hold" rating on shares of Accolade in a report on Wednesday, January 8th. Finally, Leerink Partners reiterated a "market perform" rating on shares of Accolade in a research note on Wednesday, January 8th. Thirteen analysts have rated the stock with a hold rating and one has assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $6.51.

Accolade Price Performance

Accolade stock remained flat at $7.02 during mid-day trading on Thursday. The stock's 50 day moving average is $6.97 and its 200-day moving average is $5.26. The company has a debt-to-equity ratio of 0.67, a current ratio of 2.63 and a quick ratio of 2.63. The firm has a market capitalization of $575.59 million, a P/E ratio of -3.12 and a beta of 2.10. Accolade, Inc. has a 12-month low of $3.08 and a 12-month high of $9.67.

About Accolade

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and primary care physicians.